UK’s NICE recommends Piqray® (alpelisib) and Trodelvy® (sacituzumab govitecan) for advanced breast cancer

The UK’s National Institute for Health and Care Excellence (NICE, UK) recently published final draft guidance recommending two breast cancer treatments Piqray® (alpelisib) and Trodelvy® (sacituzumab govitecan), making them immediately available to patients on the NHS. Since 2018, NICE has retained a 100% approval rate for breast cancer medicines. Piqray made by Novartis Pharmaceuticals UK, is the first targeted treatment for locally progressed or metastatic hormone receptor-positive, HER2-negative, PIK3CA-mutated breast cancer. The treatment is an option for adults whose cancer has progressed after treatment with a CDK4/6 inhibitor plus an aromatase inhibitor. Taken as a once-a-day tablet, in combination with...